J. Goldman & Co’s Protagonist Therapeutics PTGX Stock Holding History

J. Goldman & Co’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Sell	9,714 -36,611	-79%	-$3.24M	0.03%	414
2025 Q4	$4.05M	Buy	46,325 +28,257	+156%	+$2.31M	0.11%	226
2025 Q3	$1.2M	Sell	18,068 -17,760	-50%	-$1.01M	0.03%	318
2025 Q2	$1.98M	Sell	35,828 -29,416	-45%	-$1.41M	0.05%	277
2025 Q1	$3.16M	Buy	+65,244	New	+$2.73M	0.08%	251
2022 Q2	–	Sell	-81,873	Closed	-$1.94M	–	442
2022 Q1	$1.94M	Sell	81,873 -48,644	-37%	-$1.37M	0.09%	206
2021 Q4	$4.46M	Buy	+130,517	New	+$4.13M	0.25%	117
2021 Q3	–	Sell	-19,986	Closed	-$897K	–	438
2021 Q2	$897K	Sell	19,986 -29,593	-60%	-$977K	0.03%	287
2021 Q1	$1.28M	Buy	49,579 +11,238	+29%	+$284K	0.04%	282
2020 Q4	$773K	Buy	38,341 +15,125	+65%	+$326K	0.04%	254
2020 Q3	$454K	Sell	23,216 -26,143	-53%	-$491K	0.03%	257
2020 Q2	$872K	Buy	+49,359	New	+$619K	0.05%	201

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

J. Goldman & Co's PTGX Position: Q1 2026 in Review

J. Goldman & Co reduced its Protagonist Therapeutics (PTGX) stake by 79% in Q1 2026, selling an estimated $3.24M and leaving 9,714 shares worth $1.02M. The position accounts for 0.03% of the portfolio, ranked #414.

J. Goldman & Co first reported a position in PTGX in Q2 2020 and has held it in 12 quarters since. The position peaked at $4.46M in Q4 2021. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

J. Goldman & Co held 9,714 shares of Protagonist Therapeutics worth $1.02M as of Q1 2026.
J. Goldman & Co sold 36,611 Protagonist Therapeutics shares in Q1 2026, an estimated $3.24M.
Protagonist Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #414 holding.
J. Goldman & Co first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 12 quarters since.
J. Goldman & Co's Protagonist Therapeutics position peaked at $4.46M in Q4 2021.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.